Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
ABSTRACT
To evaluate the degree of periodontal tissue destruction, aspartate aminotransferase (AST) levels in the gingival crevicular fluid (GCF) are utilized as a predictor of periodontal therapy. We have previously shown that the usefulness of AST activities [periodontal tissue monitor (PTM) values] using a PTM-kit to evaluate the effects of initial periodontal therapy and periodontal regeneration therapy by enamel matrix derivative (EMD). This prospective, longitudinal study was conducted using 38 healthy and 80 periodontitis sites with probing depth (PD) of 5 - 10 mm for guided tissue regeneration (GTR) and EMD from 36 patients. GCF samples were used to evaluate PTM values at base line (BL) and after 6 months of surgeries (re-evaluation: RE), and periodontal examinations were performed concurrently. PTM values at BL were statistically improved at RE, accompanied by the improvement of periodontal parameters in both groups. PTM values and PD, and the clinical attachment level (CAL) showed high correlations. PD, CAL and bleeding on probing (BOP) were highly correlated with PTM values in both groups, whereas only PD showed a significant correlation with PTM values at RE in the GTR group. Change in the amounts of PD, CAL and BOP between BL and RE in both groups showed no correlation with PTM values. In the negative PTM value sites at BL in EMD group, the mean PD was significantly reduced at RE compared with positive PTM sites at BL. PTM values are able to be utilized as the biochemical predictor of prognosis after periodontal regeneration therapy.

Abstrak :

Latar Belakang: Talasemia I² mayor merupakan penyakit dengan gen carrier yang cukup banyak ditemukan di Indonesia sehingga dibutuhkan penelitian lebih lanjut tentang pola talasemia β mayor terlebih lagi penderitanya mengalami inefektif hematopoesis sehingga pasien talasemia I² mayor sangat bergantung dengan terapi transfusi dan kelasi untuk bertahan hidup sehingga penelitian ini bertujuan untuk mengetahui efek yang ditimbulkan dari kepatuhan terapi kelasi pada populasi Indonesia terhadap kadar alanin aminotransferase, aspartat aminotransferase, dan AST to patelet ratio index (APRI) score.

Metode: Penelitian ini menggunakan metode observatif cross sectional dan seluruh partisipan penelitian adalah pasien RSCM Kiara. Data kepatuhan pasien didapat dari kuisioner morisky medication adherence scale -8 serta pertanyaan singkat alasan ketidakpatuhan dalam terapi yang akan dicocokan dengan data laboratorium pasien pada rekam medik elektronik dan selanjutnya data dianalisis menggunakan uji bivariat nonparametrik Kruskal-Wallis dan uji Post-Hoc Mann-Whitney.

Hasil: Tidak ditemukan adanya hubungan yang bermakna antara kepatuhan terapi kelasi terhadap kadar alanin amintotransferase, aspartat aminotransferase, dan APRI score namun, ditemukan hubungan yang bermakna pada umur, lama transfusi, dan jenis kelator terhadap nilai APRI score.

Kesimpulan: Tidak ditemukan adanya hubungan bermakna pada kepatuhan terapi kelasi terhadap kadar alanin aminotransferase, aspartat aminotransferase, dan APRI score namun dibutuhkan penelitian lebih lanjut untuk mengkonfirmasi hasil tersebut dikarenakan terdapat keterbatasan dalam penelitian.

 

---

Background: Thalassemia I² major is a disease with carrier gene common enough to be found in Indonesia therefore further research was needed to know the exact pattern and characteristics of thalassemia I² major because the patients has ineffective hematopoiesis depend their life with transfusion and chelation therapy to survive therefore it need further research to know the effect of chelation therapy for population in Indonesia with alanin aminotransferase, aspartat aminotransferase, and AST to platelet ratio index (APRI) score level.

Methods: This study used observative cross sectional method and all of the participants are patients at RSCM Kiara. Participants compliance were measured by morisky medication adherence scale-8 with some adjustment to know the reason why participants isnt complying with therapy and will be compared with laboratory result through electronic medical record then both results were then analyzed non-parametrically using Kruskal-Wallis followed by Mann-Whitney for Post-Hoc.

Results: There arent any correlation between chelation therapy compliance with aspartat aminotransferase, alanine aminotransferase, and AST to platelet ratio index score level but it has been found that age, transfusion duration, and type of chelator have some degree of correlation.

Conclusion: There arent any correlation between chelation therapy compliance with aspartat aminotransferase, alanine aminotransferase, and AST to platelet ratio index score level but the result need further research to confirm the result because this research has its own degree of limitation

Abstrak :
Latar Belakang: Fibrosis hati disebabkan cedera hati kronis akan menjadi sirosis. Vesikel ekstraseluler (VE) dan Hepatocyte Growth Factor (HGF) banyak dipelajari sebagai terapi fibrosis dan regenerasi hati. Penelitian ini memanfaatkan kombinasi VE dan recombinant human-HGF ( rh-HGF) sebagai terapi alternatif fibrosis hati pada model tikus ligasi duktus bilier (LDB). Metode: Sebelas tikus Sprague Dawley (SD) menjalani LDB, 5 tikus kontrol dan 6 tikus mendapat perlakuan injeksi VE 150 uL dan rh-HGF 0,1 mg intravena sejak 3 minggu pasca LDB, selama 7 hari. Satu tikus kontrol diterminasi 3 minggu pasca LDB sebagai data dasar. Tikus-tikus kelompok kontrol dan perlakuan diterminasi pada 1 hari dan 2 minggu setelah injeksi terakhir. Dilakukan penilaian skor Laennec hati serta kadar HGF, alanine aminotransferase (ALT) dan aspartate aminotransferase (AST). Hasil: Histopatologi 3 minggu pasca LDB menunjukkan skor Laennec 2. Skor fibrosis kelompok kontrol (KK) dan kelompok perlakuan (KP) 1 minggu dan 2 minggu pasca injeksi VE dan rh-HGF seluruhnya dengan skor 2. Kadar HGF pada KP lebih rendah secara signifikan dibandingkan dengan KK 1 hari pasca injeksi terakhir (1,35+0,06 vs 1,53+0,06; p<0,001), semakin menurun setelah 2 minggu pasca injeksi terakhir namun tidak bermakna secara statistik 0,83 (0,73-0,84) vs 0,76 (0,73-0,80) p=0,248). Kadar AST 1 hari pasca injeksi terakhir; KK 1,66+0,05 KP 0,91+0,12 debgan p = 0,001. Setelah 2 minggu pasca injeksi; kadar AST pada kedua kelompok menurun 1,12 (1,11-1,22) vs (0,96+0,03); p=0,021). Kadar ALT pada kelompok perlakuan lebih rendah secara signifikan pada 1 hari pasca injeksi dan 2 minggu pasca injeksi dengan nilai p<0,001 dan 0,033a ......Background: Fibrosis of the liver due to a chronic liver injury will become cirrhosis at the end-stage. The Extracellular Vesicles (EV) and hepatocyte growth factor (HGF) are recently learned as much as fibrosis and liver regeneration therapy. This study aims to know the result of using a combination of EV and recombinant human HGF (rh-HGF) as an alternative therapy due to liver fibrosis on the rat bile duct ligation (BDL) model. Methods: Eleven BDL Sprague Dawley (SD) were divided into two groups, five mice as the untreated control group and six mice as the treatment group was getting an EV 150 ul and rh-hgf 0.1 mg intravenous injection three weeks after BDL, for seven days. One control rat is expanded three weeks after BDL as baseline data. The control and treatment group mice were projected at day one and two weeks after the final injection. This study was assessed from liver fibrosis by using Laennec score, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and Hepatocyte Growth Factor (HGF) level. Results: Scoring of histopathology by using the Laennec score at 3 weeks after BDL was 2.Meanwhile scoring of fibrosis of the control group and treatment group at 1 week and 2weeks after ve and rh-hgf injection were 2. HGF level of the treatment group was lower significantly than control group at day 1 after last injection (1,35+0,06 vs 1,53+0,06; p<0,001), and within 2 weeks, the number of HGF levels decreased but statistically insignificant; 0,83 (0,73-0,84) vs 0,76 (0,73-0,80) p=0,248). AST level at day 1 after last injection; control group vs treatment group ;1,66+0,05 vs 0,91+0,12, p value = 0,001. 2 weeks after injection; AST level for both group were become lower 1,12 (1,11-1,22) vs (0,96+0,03); p=0,021), and ALT level on treatment group was significantly lower at day 1 and 2 weeks after injection with p value <0,001 and 0, 033a

Abstrak :
Background: Hepatitis B is endemic in Indonesia and treatment response need to be monitored during and after antiviral therapy. Liver stiffness measurement and alanine aminotransferase to platelet ratio index (APRI) are noninvasive method to detect liver fibrosis available in Indonesia. However, little is known about their ability to evaluate treatment response in chronic hepatitis B (CHB) patients in Indonesia. This study aimed to investigate liver stiffness changes by transient elastography (TE) and APRI before and after one year oral antiviral treatment in CHB patients and the correlation between TE and APRI. Methods: this study was retrospective cohort on CHB patients in CiptoMangunkusumo Hospital, Jakarta who uderwent treatment between January 2012 and December 2014. Patients received oral antiviral treatment with newer nucleoside analogues (entecavir or telbivudine) for at least one year. TE and APRI were obtained before and after treatment. TE and APRI reductions were analyzed statistically with Spearmans test. Results: a total of 41 patients were enrolled in this study. Median liver stiffness value was significantly reduced from 10.8 to 5.9 kPa after oral antiviral treatment (p<0.001, Wilcoxons test). Median APRI was also significantly reduced from 1.13 to 0.43 after treatment (p<0.001, Wilcoxons test). The correlation between liver stiffness and APRI before treatment was weak (r=0.40), but it was strong after treatment (r=0.73). Conclusion: the liver stiffness measured with transient elastography and APRI significantly decreased after one year of antiviral treatment in chronic HBV patients. There was a significant correlation between TE and APRI after one year of treatment.